Diaryl urea PI3K/mTOR/HDAC multi-target inhibitor as well as pharmaceutical composition and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a diarylurea PI3K/mTOR/HDAC multi-target inhibitor as well as a pharmaceutical composition and application of the diarylurea PI3K/mTOR/HDAC multi-target inhibitor. The diarylurea PI3K/mTOR/HDAC multi-target inhibitor disclosed by the invention belongs to a single-molecule multi-target inhibitor, has multiple action mechanisms, and has the characteristics of good curative effect and small toxicity. The compound has the characteristic of effectively inhibiting a plurality of PI3K subtype kinases, mTOR kinases and HDAC proteins. The structure of the diarylurea PI3K/mTOR/HDAC multi-target inhibitor is as shown in the specification..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 12. Mai Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

ZHANG JIQUAN [VerfasserIn]
SUN QIWEN [VerfasserIn]
WU CHUNFENG [VerfasserIn]
MA DAN [VerfasserIn]
TANG LEI [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-05-12, Last update posted on www.tib.eu: 2023-10-31, Last updated: 2023-11-03

Patentnummer:

CN116102545

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018336108